Cancer chronotherapy: Principles, applications, and perspectives
Tóm tắt
Cell physiology is regulated along the 24‐hour timescale by a circadian clock, which is comprised of interconnected molecular loops involving at least nine genes. The cellular clocks are coordinated by the suprachiasmatic nucleus, a hypothalamic pacemaker that also helps the organism adjust to environmental cycles. The rest‐activity rhythm is a reliable marker of the circadian system function in both rodents and humans. This circadian organization is responsible for predictable changes in the tolerability and efficacy of anticancer agents, and possibly also may be involved in tumor promotion or growth.
Expected least toxic times of chemotherapy were extrapolated from experimental models to human subjects with reference to the rest‐activity cycle. The clinical relevance of the chronotherapy principle (i.e., treatment administration as a function of rhythms) has been investigated previously in randomized multicenter trials.
In the current study, chronotherapeutic schedules were used to safely document activity of the combination of oxaliplatin, 5‐fluorouracil, and leucovorin against metastatic colorectal carcinoma and to establish new medicosurgical management for this disease, and were reported to result in unprecedented long‐term survival.
Chronotherapy concepts appear to offer further potential to improve current cancer treatment options as well as to optimize the development of new anticancer or supportive agents. Cancer 2003;97:155–69. © 2003 American Cancer Society.
DOI 10.1002/cncr.11040
Từ khóa
Tài liệu tham khảo
BouzahzahB. Influence de différents promoteurs sur la prolifération cellulaire du foie de rat normal et précancéreux : rôle des corticoïdes et des rythmes circadiens [Ph.D. thesis]. Liàge Belgium: Université de Liège 1990.
Sothern RB, 1978, Circadian temperature rhythm in LOU rats with and without immunocytoma during polychronochemotherapy with adriamycin and cis‐diamminedichloroplatinum, Chronobiologia., 5, 216
Voutilainen A, 1953, Uber die 24‐stunden‐rhythmik der mitozfrequenz in malignen tumoren, Acta Pathol Microbiol Scand., 99, 1
Tahti E, 1956, Studies of the effect of X‐irradiation on 24 hour variations in the mitotic activity in human malignant tumors, Acta Pathol Microbiol Scand., 117, 1
Garcia‐Sainz M, 1966, Mitotic rhythms in human cancer reevaluated by electronic computer programs. Evidence for chronopathology, J Natl Cancer Inst., 37, 279, 10.1093/jnci/37.3.279
Zagula‐Mally ZW, 1979, Chronopharmacology, 399
Klevecz R, 1987, Circadian gating of S phase in human ovarian cancer, Cancer Res., 47, 6267
Smaaland R, 1993, DNA synthesis and ploidy in non‐Hodgkin's lymphomas demonstrate variation depending on circadian stage of cell sampling, Cancer Res., 53, 3129
Gautherie M, 1974, Circadian rhythm alteration of skin temperature in breast cancer, Chronobiologia., 4, 1
Mansfield CM, 1973, Circadian rhythm in the skin temperature of normal and cancerous breasts, Int J. Chronobiol., 1, 235
BenavidesM. Cancer avancé de l'ovaire: approche chronobiologique comme nouvelle stratégie du traitement et de la surveillance clinique et biologique [Ph.D. thesis]. Paris: Université Paris XI 1991.
Mormont MC, 2000, Marked 24‐h rest/activity rhythms are associated with better quality of life, better response and longer survival in patients with metastatic colorectal cancer and good performance status, Clin Cancer Res., 6, 3038
Mormont MC, 1989, Chronopharmacology: cellular and biochemical interactions, 395
Lévi F, 1982, Reduction of cis‐diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing, Cancer Res., 42, 950
Boughattas N, 1989, Circadian rhythm in toxicities and tissue uptake of 1,2‐diamminocyclohexane (trans‐1) oxalatoplatinum (II) in mice, Cancer Res., 49, 3362
Mormont MC, 1986, Circadian dependency of vinblastine toxicity, Ann Rev Chronopharmacol., 3, 187
Filipski E, 1999, Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388‐bearing mice, J Pharmacol Exp Ther., 289, 231
Tampellini M, 1998, Circadian rhythm in docetaxel tolerability and efficacy in mice, Cancer Res., 58, 3896
Zhang R, 1993, Relationship between circadian‐dependent toxicity of 5‐fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy, Cancer Res., 53, 2816
Ohdo S, 1997, Cell cycle‐dependent chronotoxicity of irinotecan hydrochloride in mice, J Pharmacol Exp Ther., 283, 1383
Petit E, 1988, Circadian varying plasma concentration of 5‐FU during 5‐day continuous venous infusion at constant rate in cancer patients, Cancer Res., 48, 1676
Fleming GF, 1994, Circadian variation of 5‐fluorouracil (5‐FU) and cortisol plasma levels during continuous‐infusion 5‐FU and leucovorin (LV) in patients with hepatic or renal dysfunction, Proc Am Soc Clin Oncol., 13, 139
Takimoto CH, 1999, High inter‐ and intrapatient variation in 5‐fluorouracil plasma concentrations during a prolonged drug infusion, Clin Cancer Res., 5, 1347
Lévi F, 1986, Circadian‐varying plasma pharmacokinetics of doxorubicin (DOX) despite continuous infusion at constant rate, Proc Am Assoc Cancer Res., 27, 693
Focan C, 1989, Vindesine en perfusion continue de 48 heures (suivie de cisplatine) dans le cancer pulmonaire avancé. Données chronopharmacocinétiques et efficacité clinique, Bull Cancer., 76, 909
Squalli A, 1989, Clinical chronopharmacokinetics of doxorubicin (DXR), Ann Rev Chronopharmacol., 5, 393
Harris B, 1990, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5‐fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5‐fluorouracil by protracted continuous infusion, Cancer Res., 50, 197
DekaAC. Application of chronobiology to radiotherapy to tumours of the oral cavity [M.D. thesis]. Chandigarh India: Post‐Graduate Institute of Medical Education and Research 1975.
Deprés‐Brummer P, 1995, Circadian rhythm modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5‐fluorouracil and folinic acid: preliminary results of a Phase I trial, J Infus Chemother., 5, 144
Focan C, 1995, Ambulatory chronotherapy with 5‐fluorouracil, folinic acid and carboplatin for advanced non‐small cell lung cancer. A phase II feasibility trial, J Infus Chemother., 5, 148
Lévi F, 1995, A Phase I‐II trial of five‐day continuous intravenous infusion of 5‐fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer, J Infus Chemother., 5, 153
Deprés‐Brummer P, 1995, Light‐induced suppression of the rat circadian system, Am J Physiol., 268, r1111
Curé H, 2000, Phase II trial of chronomodulated infusion of high‐dose 5‐fluorouracil and l‐folinic acid in previously untreated patients with metastatic colorectal cancer, Anticancer Res., 20, 4649
Bjarnason GA, 1998, Phase II study of 5‐fluorouracil (FU) and leucovorin (LV) by a 14 day chronomodulated infusion in patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol, 17, 275a
Brienza S, 1993, Intensified (every 2 weeks) chronotherapy with 5‐fluorouracil (5‐FU), folinic acid (FA) and oxaliplatin (L‐OHP) in previously treated patients with metastatic colorectal cancer, Proc Am Soc Clin Oncol., 12, 197
Giacchetti S, 2002, Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first line treatment of metastatic colorectal cancer. Update. Classic papers and current comments, highlights of gastrointestinal cancer research. A best of JCO, J Clin Oncol., 6, 885